CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 ...

GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

The biggest fallers on the FTSE 100 were Diageo, down 92.5p to 2235p, DCC, down 195p to 5300p, Croda, down 103p to 3110p, ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...

Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price ...

Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...